Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer
- 1 October 2007
- journal article
- Published by BMJ in International Journal of Gynecologic Cancer
- Vol. 17 (6), 1238-1244
- https://doi.org/10.1111/j.1525-1438.2007.00931.x
Abstract
Para-aortic lymphadenectomy is part of staging in early epithelial ovarian cancer (EOC) and could be part of therapy in advanced EOC. However, only a minority of patients receive therapy according to guidelines or have attendance to a specialized unit. We analyzed pattern of lymphatic spread of EOC and evaluated if clinical factors and intraoperative findings reliably could predict lymph node involvement, in order to evaluate if patients could be identified in whom lymphadenectomy could be omitted and who should not be referred to a center with capacity of performing extensive gynecological operations. Retrospective analysis was carried out of all patients with EOC who had systematic pelvic and para-aortic lymphadenectomy during primary cytoreductive surgery. One hundred ninety-five patients underwent systematic pelvic and para-aortic lymphadenectomy. Histologic lymph node metastases were found in 53%. The highest frequency was found in the upper left para-aortic region (32% of all patients) and between vena cava inferior and abdominal aorta (36%). Neither intraoperative clinical diagnosis nor frozen section of pelvic nodes could reliably predict para-aortic lymph node metastasis. The pathologic diagnosis of the pelvic nodes, if used as diagnostic tool for para-aortic lymph nodes, showed a sensitivity of only 50% in ovarian cancer confined to the pelvis and 73% in more advanced disease. We could not detect any intraoperative tool that could reliably predict pathologic status of para-aortic lymph nodes. Systematic pelvic and para-aortic lymphadenectomy remains part of staging in EOC. Patients with EOC should be offered the opportunity to receive state-of-the-art treatment including surgeryKeywords
This publication has 33 references indexed in Scilit:
- Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 TrialJournal of Clinical Oncology, 2005
- Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical TrialJNCI Journal of the National Cancer Institute, 2005
- Systematic lymphadenectomy in advanced epithelial ovarian cancer: two decades of uncertainty resolved.JNCI Journal of the National Cancer Institute, 2005
- Drug sensitivity-related benefit of systematic lymphadenectomy during cytoreductive surgery in optimally debulked stages IIIc and IV ovarian cancerGynecologic Oncology, 2004
- Can we rely on the size of the lymph node in determining nodal metastasis in ovarian carcinoma?International Journal of Gynecologic Cancer, 2003
- Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma? A DEGOG* StudyJournal of Surgical Oncology, 2002
- Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal diseaseInternational Journal of Gynecologic Cancer, 1997
- Systematic Pelvic and Paraaortic Lymphadenectomy for Advanced Ovarian Cancer: Prognostic Significance of Node MetastasesGynecologic Oncology, 1996
- Prognostic evaluation of lymphadenectomy for epithelial ovarian cancerJournal of Surgical Oncology, 1995
- Retroperitoneal Lymphadenectomy, Including the Para-aortic Nodes in Patients with Stage III Ovarian CancerAmerican Journal of Clinical Oncology, 1994